138 related articles for article (PubMed ID: 24816199)
1. Urban and rural safety net health care system clinics: no disparity in HPV4 vaccine completion rates.
Sandri KJ; Verdenius I; Bartley MJ; Else BM; Paynter CA; Rosemergey BE; Harris GD; Malnar GJ; Harper SM; Griffith RS; Bonham AJ; Harper DM
PLoS One; 2014; 9(5):e96277. PubMed ID: 24816199
[TBL] [Abstract][Full Text] [Related]
2. Quantifying clinical HPV4 dose inefficiencies in a safety net population.
Harper DM; Verdenius I; Ratnaraj F; Arey AM; Rosemergey B; Malnar GJ; Wall J
PLoS One; 2013; 8(11):e77961. PubMed ID: 24223131
[TBL] [Abstract][Full Text] [Related]
3. In a safety net population HPV4 vaccine adherence worsens as BMI increases.
Harper DM; Else BM; Bartley MJ; Arey AM; Barnett AL; Rosemergey BE; Paynter CA; Verdenius I; Harper SM; Harris GD; Groner JA; Malnar GJ; Wall J; Bonham AJ
PLoS One; 2014; 9(7):e103172. PubMed ID: 25076128
[TBL] [Abstract][Full Text] [Related]
4. The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series.
Harper DM; Verdenius I; Harris GD; Barnett AL; Rosemergey BE; Arey AM; Wall J; Malnar GJ
Prev Med; 2014 Apr; 61():20-5. PubMed ID: 24440159
[TBL] [Abstract][Full Text] [Related]
5. Predictors of three dose on-time compliance with HPV4 vaccination in a disadvantaged, underserved, safety net population in the US Midwest.
Verdenius I; Harper DM; Harris GD; Griffith RS; Wall J; Hempstead LK; Malnar GJ; Bekkers RL
PLoS One; 2013; 8(8):e71295. PubMed ID: 23951123
[TBL] [Abstract][Full Text] [Related]
6. Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics.
Tiro JA; Pruitt SL; Bruce CM; Persaud D; Lau M; Vernon SW; Morrow J; Skinner CS
Vaccine; 2012 Mar; 30(13):2368-75. PubMed ID: 22108490
[TBL] [Abstract][Full Text] [Related]
7. Associations between prior HPV4 vaccine doses and cervical cancer screening participation.
Boone SD; Pinkston CM; Baumgartner KB; Baumgartner RN; Harper SM; Bonham AJ; Paynter CA; Harper DM
Cancer Epidemiol; 2016 Jun; 42():108-14. PubMed ID: 27100836
[TBL] [Abstract][Full Text] [Related]
8. HPV Vaccination Completion and Compliance with Recommended Dosing Intervals Among Female and Male Adolescents in an Inner-City Community Health Center.
Wilson RM; Brown DR; Carmody DP; Fogarty S
J Community Health; 2015 Jun; 40(3):395-403. PubMed ID: 25312867
[TBL] [Abstract][Full Text] [Related]
9. Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals.
Russell K; Dunne EF; Kemper AR; Dolor RJ; Unger ER; Panicker G; Markowitz LE; Walter EB
Vaccine; 2015 Apr; 33(16):1953-8. PubMed ID: 25744229
[TBL] [Abstract][Full Text] [Related]
10. Safety of quadrivalent human papillomavirus vaccine administered routinely to females.
Klein NP; Hansen J; Chao C; Velicer C; Emery M; Slezak J; Lewis N; Deosaransingh K; Sy L; Ackerson B; Cheetham TC; Liaw KL; Takhar H; Jacobsen SJ
Arch Pediatr Adolesc Med; 2012 Dec; 166(12):1140-8. PubMed ID: 23027469
[TBL] [Abstract][Full Text] [Related]
11. HPV Vaccination Coverage Among US Teens Across the Rural-Urban Continuum.
Swiecki-Sikora AL; Henry KA; Kepka D
J Rural Health; 2019 Sep; 35(4):506-517. PubMed ID: 30703854
[TBL] [Abstract][Full Text] [Related]
12. Long-term study of a quadrivalent human papillomavirus vaccine.
Ferris D; Samakoses R; Block SL; Lazcano-Ponce E; Restrepo JA; Reisinger KS; Mehlsen J; Chatterjee A; Iversen OE; Sings HL; Shou Q; Sausser TA; Saah A
Pediatrics; 2014 Sep; 134(3):e657-65. PubMed ID: 25136050
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.
Stokley S; Jeyarajah J; Yankey D; Cano M; Gee J; Roark J; Curtis RC; Markowitz L; ;
MMWR Morb Mortal Wkly Rep; 2014 Jul; 63(29):620-4. PubMed ID: 25055185
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2013 Jul; 62(29):591-5. PubMed ID: 23884346
[TBL] [Abstract][Full Text] [Related]
15. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011.
Schmidt MA; Gold R; Kurosky SK; Daley MF; Irving SA; Gee J; Naleway AL
J Adolesc Health; 2013 Nov; 53(5):637-41. PubMed ID: 24138765
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting completion of the human papillomavirus vaccine series.
Gold R; Naleway A; Riedlinger K
J Adolesc Health; 2013 Apr; 52(4):427-32. PubMed ID: 23298984
[TBL] [Abstract][Full Text] [Related]
17. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
[TBL] [Abstract][Full Text] [Related]
18. Compliance with recommended dosing intervals for HPV vaccination among females, 13-17 years, National Immunization Survey-Teen, 2008-2009.
Dorell CG; Stokley S; Yankey D; Markowitz LE
Vaccine; 2012 Jan; 30(3):503-5. PubMed ID: 22119587
[TBL] [Abstract][Full Text] [Related]
19. Trends in Male and Female Genital Warts Among Adolescents in a Safety-Net Health Care System 2004-2013: Correlation With Introduction of Female and Male Human Papillomavirus Vaccination.
Perkins RB; Legler A; Hanchate A
Sex Transm Dis; 2015 Dec; 42(12):665-8. PubMed ID: 26562694
[TBL] [Abstract][Full Text] [Related]
20. Barriers and facilitators to HPV vaccine uptake among US rural populations: a scoping review.
Peterson CE; Silva A; Holt HK; Balanean A; Goben AH; Dykens JA
Cancer Causes Control; 2020 Sep; 31(9):801-814. PubMed ID: 32537702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
